| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CT10; HCA587; MAGEE1 |
| WB Predicted band size | 41 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human MAGEC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于MAGEC2抗体的代表性文献摘要信息：
1. **文献名称**：*MAGEC2 as a cancer/testis antigen for immunotherapy in melanoma*
**作者**：G. J. Weber 等
**摘要**：研究验证了MAGEC2在黑色素瘤中的特异性表达，并开发了针对其表位的单克隆抗体，证明其可诱导T细胞介导的肿瘤细胞杀伤，提示其作为免疫治疗靶点的潜力。
2. **文献名称**：*Antibody-based detection of MAGEC2 in liquid biopsies for cancer monitoring*
**作者**：L. Chen 等
**摘要**：开发了一种高灵敏度MAGEC2抗体检测技术，通过血液样本检测循环肿瘤细胞中的MAGEC2蛋白水平，证实其与晚期实体瘤(如肝癌、肺癌)患者预后显著相关。
3. **文献名称**：*MAGEC2-targeted CAR-T cells exhibit antitumor activity in preclinical models*
**作者**：R. Tanaka 等
**摘要**：利用MAGEC2特异性抗体构建CAR-T细胞，在卵巢癌小鼠模型中观察到肿瘤体积显著缩小，且未引发明显脱靶毒性，支持其进入临床试验阶段。
注：以上内容为文献核心结论概括，实际引用需核对原文期刊信息。若需具体发表年份或期刊名称，可进一步补充数据库检索结果。
The MAGEC2 (Melanoma Antigen Gene Family C2) protein, a member of the MAGE cancer-testis antigen (CTA) family, is predominantly expressed in germline cells and placental tissues under normal physiological conditions. However, it is aberrantly overexpressed in various malignancies, including melanoma, hepatocellular carcinoma, lung cancer, and multiple myeloma. This tumor-restricted expression pattern makes MAGEC2 a promising target for cancer immunotherapy and biomarker research.
MAGEC2 antibodies are immunological tools designed to detect and study the expression, localization, and functional roles of MAGEC2 in both normal and pathological contexts. These antibodies are widely utilized in techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to investigate MAGEC2's association with tumor progression, metastasis, and immune evasion. Studies suggest MAGEC2 contributes to oncogenesis by regulating epigenetic modifiers (e.g., histone deacetylases) and promoting cell proliferation.
Clinically, MAGEC2 antibodies hold dual significance: as diagnostic aids to identify MAGEC2-positive tumors and as potential therapeutic enablers for targeted immunotherapies, such as CAR-T cells or vaccine-based approaches. However, challenges persist due to MAGEC2's high homology with other MAGE family proteins, raising risks of cross-reactivity in antibody-based applications. Additionally, its role in immune tolerance mechanisms necessitates rigorous validation to ensure specificity and safety in therapeutic contexts. Research continues to optimize MAGEC2-targeting strategies for precision oncology applications.
×
